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Visceral leishmaniasis (VL), caused by the protozoan parasite Leishmania donovani, is a global 
health problem affecting millions of people worldwide. Treatment of VL largely depends on 
therapeutic drugs such as pentavalent antimonials, amphotericin B, and others, which have major 
drawbacks due to drug resistance, toxicity, and high cost. In this study, for the first time, we have 
successfully demonstrated the synthesis and antileishmanial activity of the novel sterol 
pentalinonsterol (PEN), which occurs naturally in the root of a Mexican medicinal plant, 
Pentalinon andrieuxii. In the experimental BALB/c mouse model of VL induced by infection with 
L. donovani, intravenous treatment with liposome-encapsulated PEN (2.5 mg/kg) led to a 
significant reduction in parasite burden in the liver and spleen. Furthermore, infected mice treated 
with liposomal PEN showed a strong host-protective TH1 immune response characterized by IFN-
γ production and formation of matured hepatic granulomas. These results indicate that PEN could 
be developed as a novel drug against VL.
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Visceral leishmaniasis (VL) is caused by the obligate intracellular parasites Leishmania 
donovani and Leishmania infantum chagasi via transmission by a sand fly vector. Half a 
million people are infected with VL, and over 60 000 succumb to the disease annually. The 
WHO classifies VL as a neglected tropical disease of global health concern. As a potentially 
life-threatening disease, VL is characterized by parasitic invasion of the blood and 
reticuloendothelial system, which affects internal organs such as the spleen, liver, and bone 
marrow.1 There are currently no licensed vaccines, and chemotherapy is the mainstay to 
combat the disease. Generally, treatments utilize antileishmanial drugs such as sodium 
stibogluconate (SSG), pentamidine, amphotericin B (AmpB), liposomal AmpB, miltefosine, 
and others.2 These drugs suffer from significant drawbacks, including the need for parenteral 
routes of administration, poor patient compliance due to long treatment lengths and toxicity, 
and/or high cost, which limit their use in disease-endemic regions. For more than 50 years, 
the most common treatment has been antimony, which has potentially cardiotoxic side 
effects.3 Additionally, AmpB has been associated with nephrotoxicity.4 The only promising 
oral treatment, miltefosine (Impavido, Miltex), is frequently unusable because of its 
potential teratogenicity5 and low tolerable doses,6 which are exacerbated by a long half-life. 
Other antileishmanial treatments that are currently under clinical development do not offer 
new alternatives to patients because they are either reformulations of current antileishmanial 
drugs, combination therapies, or the result of therapeutic switching. In addition, the 
emergence of antimonial-resistant strains of VL is rapidly increasing worldwide. Areas like 
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Bihar, India, are confronting an epidemic of antimony-resistant VL infections (close to 70% 
of cases), likely due to poor patient compliance.7 Additionally, drug resistance has been 
reported with AmpB8 and miltefosine.9 Because of the emergence of drug-resistant 
parasites, high drug toxicity, and lower patient compliance due to treatment costs,10–13 there 
is an immediate requirement for safe, cost-effective, and reliable drugs that can successfully 
treat VL.
Natural products derived from plants have long proved to be an invaluable resource for 
antiparasitic drugs, and the discovery of novel agents is considered a priority by the World 
Health Organization.14,15 A number of plant-derived biomolecules have shown potential to 
inhibit many stages of leishmanial infection.16 Plants in the families Apocynaceae, Araceae, 
Cycadaceae, Fabaceae, Piperaceae, Solanaceae, and Sapindaceae are commonly used for 
treatment of cutaneous leishmaniasis (CL) in South America.12–15 Pentalinon andrieuxii 
Muell.-Arg. (syn. Urechites andrieuxii, Apocynaceae) is a plant native to the Yucatan 
Peninsula of Mexico, and its roots have been used for years by Mayan traditional healers and 
have been shown to exhibit a wide range of biological activities, including antileishmanial 
properties.17–19 Recently, we have shown in vitro antileishmanial activity in both aqueous 
and organic extracts from the roots of P. andrieuxii.20 Additionally, we have isolated 
pentalinonsterol (PEN, cholest-4,20,24-trien-3-one, 1), a new cholesterol derivative, from 
the hexanes partition of a methanol extract of the roots of P. andrieuxii.21 PEN exhibited 
potent antileishmanial activity against Leishmania mexicana promastigotes and intracellular 
amastigotes.21 Although PEN displayed efficacy in killing of L. mexicana, little is known 
about its potential mechanism for clearance. Furthermore, its effects against parasites 
causing VL have yet to be determined. However, because of the limited availability of the 
pure compound from the plant material, it was necessary to employ alternative methods to 
efficiently obtain PEN for further study. Additionally, the hydrophobicity of PEN required 
more optimized methods for parenteral delivery of this compound for use against VL.
In this study, we have demonstrated a novel and efficient method of synthesizing PEN and 
provided evidence of a potential mechanism for its inhibition of L. donovani promastigotes. 
We have also evaluated the therapeutic efficacy of PEN in both in vitro and in vivo models 
of VL. To address solubility concerns, in vivo evaluation was performed using a formulation 
of liposomal PEN, and the host immune response was evaluated to determine potential 
mechanisms of L. donovani parasite clearance.
RESULTS AND DISCUSSION
The use of natural products is gaining increased recognition as an effective approach for the 
treatment of infectious diseases. Previously, phytosterols (e.g., PEN) isolated from the 
medicinal plant P. andrieuxii showed promising biological activity against 
Leishmania.17–19,21 However, the small quantity of available natural PEN has limited its 
application, necessitating the development of a synthetic route. In the present work, PEN 
was synthesized utilizing a five-step sequence of reactions from pregnenolone (2) (Scheme 
1). The overall yield of the process was 29%, facilitating PEN production in gram quantities. 
The 1H and 13C NMR spectroscopic data for PEN were identical to those obtained and 
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previously reported for the authentic natural product. Thus, an efficient semisynthetic route 
to PEN from a readily available and inexpensive starting material was devised.
The synthetic strategy relied on an alkylation reaction to install the functionality present in 
the C17 side chain, avoiding the need for separation of Δ17, Δ20(22), and Δ20(21) olefin 
isomers obtained through previously reported approaches to sterols of this type.22–26 To 
facilitate the alkylation reaction, the C3 alcohol moiety of 2 was protected as the tert-
butyldimethylsilyl (TBS) ether. The alkylation reaction itself was accomplished via 
treatment of this methyl ketone with base in the presence of 3,3-dimethylallyl bromide (3). 
Several reaction conditions were screened for enolate generation and alkylation in this 
reaction (see the Supporting Information), but lithium tetramethylpiperidide was ultimately 
determined to provide the most satisfactory results for the transformation. With the desired 
alkylation product in hand, all that remained in order to complete the synthesis of PEN was 
the olefination of the ketone carbonyl and transformation of the protected homoallylic 
alcohol into the α,β-unsaturated enone. To our surprise, however, Wittig olefination of 
ketone 4 using methyl triphenylphosphonium bromide and BuLi failed to provide good 
yields of the olefinated product unless excess ylide (>5 equiv) was employed. As an 
alternative, the more reactive Tebbe reagent was also successfully utilized to generate 5. The 
synthesis was completed by deprotecting the silyl ether and using the standard Oppenauer 
oxidation conditions to provide PEN. This short and efficient sequence may prove to be 
advantageous over the preparation of structurally complex antileishmanial agents such as 
AmpB,27 which is produced on an industrial scale via fermentation,28 a technique that 
requires a significant amount of postprocessing. The synthetic route provided an efficient 
scalable process to obtain multigram quantities of PEN for the reported biological 
evaluation.
The effect of PEN effect on Leishmania promastigotes has been documented, but a potential 
mechanism has yet to be elucidated. Here we evaluated PEN in vitro to study its potential 
effect on VL by determining a possible mechanism against L. donovani. Figure 1 shows that 
PEN significantly decreases the content of fatty acids in lipids of L. donovani promastigotes. 
This decrease was seen to occur in a dose-dependent manner compared with untreated 
controls. The content of saturated fatty acids (palmitic acid, C16:0, and stearic acid, C18:0) 
significantly decreased in the total lipids of the PEN-treated parasites. The levels of the 
monounsaturated fatty acid (oleic acid, C18:1) and polyunsaturated fatty acids (linoleic acid, 
C18:2, arachidonic acid, 20:4, and docosahexaenoic acid, C22:6) were significantly lower in 
the total lipids of the PEN-treated parasites compared with the same in the untreated 
counterparts. The observed total loss of fatty acids suggests that PEN could have an effect 
via hydrolysis through the action of phospholipases A1 and A2 and metabolic breakdown of 
fatty acid esters in the membrane phospholipids of the parasites. These events may 
contribute to membrane leakiness and damage that lead to the death of the parasites. 
Previous work has shown that no consistent difference in fatty acids exists among species of 
Leishmania,29 so the effect of PEN on L. donovani indicates potential efficacy against a 
number of Leishmania species.
To evaluate the in vitro antileishmanial activity of synthetic PEN, different concentrations 
(0, 1, 10, 25, 50, and 100 μg/mL) were tested for activity of PEN against L. donovani 
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promastigotes and intracellular amastigotes. PEN treatment of both L. donovani 
promastigotes and amastigotes for 48 h mediated significant parasite killing (Figure 2A,C), 
although L. donovani promastigote killing by PEN was significant at higher concentrations 
(50 and 100 μg/mL) while amastigote killing was much more successful with lower levels of 
PEN (e.g., 10 and 25 μg/mL). This is encouraging because amastigote models more 
correctly represent in vivo mechanisms of drug activity.30 In addition, since PEN has higher 
activity against the amastigote form compared with the promastigote form, PEN’s potential 
primary mode of action could be directed toward the host. Encouragingly, none of the 
concentrations of PEN used for in vitro amastigote killing were within a range that was 
cytotoxic to host macrophages (Figure 2B). While these initial in vitro assays show 
promising results, it is important for potentially clinically relevant compounds to be 
formulated and tested for in vivo use.
VL involves infection of a number of internal organs, including the spleen, liver, and bone 
marrow. Therefore, systemic delivery of therapeutics is an important step to clearing 
Leishmania infection. PEN and other similar sterol compounds are limited in their ability to 
be delivered systemically. Sterols, a subgroup of steroids, show poor absorption in the 
intestine,31 limiting their ability to be delivered orally. In addition, water-insoluble 
compounds, including a majority of sterols32 and promising antimicrobial compounds 
extracted from plants,33 show very limited ability to be delivered intravenously. To 
overcome solubility concerns, we utilized liposomes to systemically deliver PEN for VL 
treatment. Liposomes have been used effectively as a delivery vehicle for hydrophobic and 
toxic compounds such as AmpB (AmBisome).34 Through the use of a formulation similar to 
that of AmBisome, PEN was incorporated into liposomes with nearly 100% efficiency. Plant 
sterol compounds such as PEN generally reside in cell membranes,35 which may explain our 
relatively high encapsulation efficiency. Liposomal encapsulation of therapeutics has been 
shown to increase the blood circulation of encapsulated drugs.36 Additionally, prior research 
has shown that by adjustment of the size or composition of liposomes, specific sites such as 
the liver, spleen, or bone marrow can be targeted.37,38 Here liposomal PEN was evaluated 
for its ability to clear infections in these sites.
When delivered intravenously to mice infected with L. donovani, liposomal PEN displayed 
64% hepatic, 83% splenic, and 57% bone marrow parasite suppression compared with 
empty liposomes (Figure 3A–C, respectively). Comparatively, the standard antileishmanial 
drug SSG (70 mg/kg) showed low clearance similar to that of mice treated with phosphate-
buffered saline (PBS) (Figure 3). The lack of clearance using this dose of SSG is consistent 
with a previous study by Carter et al.39 This has been attributed to dissimilar 
microenvironments in the liver and spleen, a low rate of blood perfusion through the spleen 
compared with the liver, and a high clearance rate of the free drug from the body, as 95% of 
the drug is excreted in the urine within 6 h of injection.40 Importantly, liposomal PEN 
successfully suppressed parasite numbers in the bone marrow, a location that has been 
shown to play an important role as a reservoir in VL infection.41 The better efficacy of PEN 
compared with SSG despite the fact that they induce comparable T cell proliferation is likely 
due to high concentrations and better intracellular bioavailability of liposome-encapsulated 
PEN compared with free SSG in the infected organs. In addition to decreasing the parasite 
load, liposomal PEN injection was well-tolerated by L. donovani-infected mice and showed 
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a decrease in the levels of serum aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) compared with treatment of infected mice with empty liposome (Figure 
4A,B, respectively). Elevated liver enzymes, such as ALT and AST, are indicative of disease 
and represent possible damage to the liver.42 Here, the ALT levels seen in mice treated with 
liposomal PEN were considered to be within the range of ALT levels for uninfected mice,43 
indicating that liposomal PEN was well-tolerated by the mice. While liposomal PEN 
suppresses the parasite burden and is well-tolerated, its effects on the immune response are 
also important.
Traditionally, effective chemotherapy against VL requires a strong T cell response.44 For 
example, successful treatment with SSG requires functional TH1 and TH2 immune 
responses.45 This limits the use of SSG treatment for immunocompromised individuals such 
as HIV+ individuals, for whom the risk of developing VL can be up to 2300 times higher 
than that for HIV– individuals.46 Mice treated with liposomal PEN showed a significantly 
higher (2-fold) increase in T cell proliferation compared with mice treated with empty 
liposome (Figure 5). Active VL is associated with an impaired cell-mediated immune 
response, which is reflected by T cell anergy, even after exposure to Leishmania-specific 
antigens.58,59 Here, supernatants taken from cultures of restimulated splenocytes isolated 
from infected mice treated with liposomal PEN showed a 10-fold increase in interferon γ 
(IFN-γ) production compared with mice treated with empty liposome (Figure 6A). 
Furthermore, Leishmania-antigen-stimulated spleen cells from PEN-treated mice produced 
significantly more interleukin 4 (IL-4) and IL-13 (Figure 6C,D), which have been shown to 
be required for immunity47 and for optimal efficacy of antileishmanial chemotherapy in VL 
caused by L. donovani.48,49 IFN-γ has been shown to be essential for the clearance of 
experimental leishmaniasis,50 and the production of IFN-γ by TH1 cells has been shown to 
be dependent on IL-12 production from dendritic cells, macrophages, and B cells.51 In this 
study, liposomal PEN treatment induced the expression of splenic IL-12 and tumor necrosis 
factor α (TNF-α) mRNA in infected mice (Figure 7B,C).
On the other hand, infected mice treated with liposomal PEN and empty liposome showed 
comparable levels of soluble or mRNA cytokines IL-10, IL-4, or IL-13 (Figure 6B–D and 
Figure 7D,E). Thus, PEN does not appear to modulate the levels of anti-inflammatory 
cytokines during infection. Interestingly, there was an increase in the IFN-γ:IL-10 and IFN-
γ:IL-4 mRNA ratios in infected mice treated with liposomal PEN compared with empty 
liposomes (Figure 7G,H), which suggests that a predominant TH1 response is a possible 
contributing factor to the in vivo antileishmanial activity.52 In addition to providing for an 
inflammatory environment, increased IFN-γ can contribute to parasite clearance through the 
formation of amastigote-clearing granulomas.53 Liposomal-PEN-treated mice had a 
significant reduction in the level of immature hepatic granulomas compared with empty-
liposome-treated mice (Figure 8). Furthermore, there was a significant increase in the 
number of parasite-free mature hepatic granulomas in the liposomal-PEN-treated mice 
compared with empty-liposome-treated mice (Figure 8). These data suggest that liposomal 
PEN promotes clearance of L. donovani, at least partially, through the formation of hepatic 
granulomas.
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Overall, this study highlights the immunotherapeutic potential of PEN for the treatment of 
VL using both in vitro and in vivo models. Liposomal PEN successfully rescued the 
impaired immune response of the L. donovani-infected host by mediating a strong pro-
inflammatory cytokine response. Additionally, it cleared parasite load in the liver, spleen, 
and bone marrow significantly better than controls, including the currently used clinical 
treatment, SSG. The results of this study strongly suggest that PEN could be developed as a 
therapy for the treatment of VL.
METHODS
Materials
All reagents were purchased from Sigma-Aldrich and used as purchased, unless otherwise 
noted. All lipids, membranes, and extruders used for liposome formulation were purchased 
from Avanti Polar Lipids. All animals used for experiments were purchased from Harlan 
Laboratories.
Synthesis of Pentalinonsterol
PEN was synthesized in five synthetic steps from commercially available 5-pregnen-3β-
ol-20-one (pregnenolone). All of the intermediates were purified utilizing silica gel flash 
column chromatography and characterized utilizing 1H and 13C NMR spectroscopy, IR 
spectroscopy, and high-resolution mass spectrometry. The experimental procedures and 
characterization data for all of the intermediates and PEN are included in the Supporting 
Information.
Evaluation of the Action of Pentalinonsterol on the Fatty Acid Composition of L. donovani 
Promastigotes
Promastigotes of L. donovani (1.5 × 107) were treated without or with PEN (5 and 10 
μg/mL) for 12 h in medium 199 containing 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin mixture in sterile 35 mm dishes in triplicate at 23.5 °C in ambient 
atmosphere. Following treatment, the parasites were washed with 1 mL of PBS and 
centrifuged at 1000g for 10 min, and the pellets were reconstituted in 500 μL of PBS. Total 
lipids were extracted from the parasites in suspension by the Folch method with chloroform/
methanol (2:1 v/v) according to the method of Parinandi and co-workers.54,55 Fatty acids in 
the total lipids containing the membrane lipids were derivatized into methyl esters by 
alkaline methanolysis and analyzed by gas chromatography–mass spectrometry (Shimadzu 
Scientific Instruments (Columbia, MD) equipped with Restek column) as described by 
Parinandi et al.54 and Hinzey et al.56 with heptadecanoic acid (C17:0) as the internal 
standard. Individual fatty acid species were expressed in μg per 1.5 × 107 parasites in control 
and treatments.
Preparation of Empty and Pentalinonsterol-Loaded Liposomes
Hydrogenated (Soy) L-α-phosphatidylcholine, 1,2-distearoyl-sn-glycero-3-[phospho-rac-(1-
glycerol)], cholesterol (ovine wool), and D-α-tocopherol (Acros Organics) with or without 
PEN (10% w/w) were placed into chloroform/methanol (9:1 v/v). The solvent was removed 
under reduced pressure using a rotary evaporator (R-200, Buchi, New Castle, DE, United 
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States) and a water bath (Buchi B-490), courtesy of Dr. Karl Werbovetz (College of 
Pharmacy, The Ohio State University), set at 60 °C to make a lipid film. The lipid film was 
reconstituted in dd-H2O for 30 min in a 60 °C water bath. Liposomes were freeze-thawed 
three times, extruded 11 times through an Avanti miniextruder/heating block with an 80 nm 
polycarbonate membrane and filter supports, and then passed through a disposable PD-10 
column (GE Healthcare). Sucrose was added to the liposomes (150% w/w) followed by 
lyophilization.
Determination of the Size and Encapsulated Pentali-nonsterol in Liposomes
Liposomes were suspended in dd-H2O, and sizing was determined using an submicron 
particle sizer (model 370, NICOMP, Santa Barbara, CA, United States), courtesy of Dr. 
Robert Lee (College of Pharmacy, The Ohio State University). Liposomes containing PEN 
were determined to be 116.9 nm in size. The encapsulation efficiency of PEN in liposomes 
was 99%, as determined by HPLC (Waters, Milford, MA, United States) using a method 
adapted from Pan et al.21 Briefly, liposomes were dissolved in methanol/dd-H2O (95:5 v/v) 
(1 mg/mL), and the PEN concentration was determined using a C18 column (150 mm × 4.6 
mm, pore size 5 μm). Samples were passed through the column at a flow rate of 1 mL min−1 
and read at a wavelength of 240 nm, and they had a retention time of 22 min.
Animals and Parasites
Syrian gold hamsters (6–8 weeks old) were used to maintain L. donovani (LV 82). L. 
donovani (LV82) parasites expressing dsRed were grown and maintained in stat4−/− BALB/c 
mice (6–8 week old; females). All of the animals were kept in a sterile facility according to 
institutional guidelines of The Ohio State University. All animal procedures were in 
accordance with and approved by the Institutional Animal Care and Use Committee 
(IACUC) of The Ohio State University.
Promastigote Assay
Log-phase dsRed-expressing L. donovani (LV82) promastigotes (1 × 106) were seeded in 1 
mL of complete RPMI-1640 medium. Parasite numbers, mobility, and morphology were 
measured at 48 h by flow cytometry using experimental and control groups of parasites with 
Quillaja saponaria saponin as a positive control.57
Amastigote Assay
Bone-marrow-derived macrophages (BMDMs) (0.5 × 106) were plated to adherence on 
round glass coverslips in a 24-well tissue culture plate. Adherent macrophages were infected 
overnight with 2.5 × 106 stationary-phase promastigotes of L. donovani parasites 
(macrophages:parasites = 1:5). Following infection, cells were washed with Hank’s balanced 
salt solution (HBSS) and cultured for 48 h with PEN. Finally, BMDMs were stained with 
Giemsa, and the infection rates, blinded by the number of parasites per 100 macrophages, 
were determined in triplicate.58
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Cytotoxicity Assay in Noninfected Macrophages
BMDMs (0.5 × 106) from BALB/c mice were cultured in a 96-well plate for 48 h with PEN 
or controls. Following 42 h, 10% Amalar blue was added to each well, and the total number 
of live cells was determined.59
In Vivo Infection and Treatment Protocol
BALB/c mice were infected with 1 × 107 amastigotes by tail vein injection. Two weeks 
postinfection, mice were treated intravenously with 100 μL of PBS, empty liposomes, 
liposomal PEN (50 μg PEN/mouse), or SSG (70 mg/kg) (Albert David Ltd., Kolkata, India).
Parasite Burden Calculation
Two weeks post treatment, mice were euthanized, and their livers and spleens were 
harvested, weighed, and sectioned to prepare impression smears. Smears were stained with 
Giemsa to tally the parasite load, which was expressed in leishmania donovan units (LDU), 
equal to the number of amastigotes per 1000 nucleated cells times the organ weight in 
grams. Additionally, bone marrow parasite counts were performed as previously 
described.60 Briefly, bone marrow was removed from the femurs of BALB/c mice, and 
smears were taken and stained with Giemsa, after which the total parasite load was 
calculated.
Histopathology
Two weeks post treatment, tissue sections from the livers of L. donovani-infected mice were 
stained using H&E stain, and histopathological examinations were performed. Liver 
granulomas were tallied as follows: (1) no reaction, (2) developing, (3) mature, and (4) 
empty.61 Liver granuloma totals are representative of the average of four or five individual 
mice.
T Cell Proliferation and Cytokine ELISA
T cell proliferation was performed as previously described.62 Briefly, 5 × 105 splenic cells 
isolated 2 weeks post treatment were added to a 96-well flat-bottom plate. An antigen recall 
assay was performed with L. donovani antigen (20 μg/mL), and proliferation was measured 
using the Alamar blue assay as previously described63 Additionally, supernatants were 
collected at 72 h of and analyzed for the production of IFN-γ, IL-12p70, IL-13, IL-4, and 
IL-10 by enzyme-linked immunosorbent assay (ELISA) (BD Pharmingen).
Quantification of Transcript Levels by Real-Time PCR
Total RNA was extracted from 50 mg of spleen tissue using TRIZOL reagent. mRNA was 
reverse-transcribed, and cDNA was amplified by real-time polymerase chain reaction (PCR) 
as described previously.64 Primers and reaction conditions were obtained from the PRIMER 
BANK Web site (Massachusetts General Hospital Primer Bank65–67). Data were normalized 
to the housekeeping gene β-actin and presented as fold induction over infected wild-type 
mice using the delta–delta CT method.
Gupta et al. Page 9













Measurement of Liver Aminotransferase Enzymes
Blood was collected in non-heparinized tubes and allowed to clot overnight at 4 °C. The 
hematology lab of The Ohio State University Veterinary Hospital analyzed serum ALT and 
AST using a Cobas C501 serum analyzer (Roche).
Statistical Analysis
Unpaired Student’s t tests were used to determine the statistical significance of differences in 
the values. A value of p < 0.05 was considered significant. The statistical significance of the 
IFN-γ:IL-4 and IFN-γ:IL-10 ratios was determined by nonparametric tests using the Mann–
Whitney U test. For fatty acid analysis, each value is the mean ± SD of three independent 
determinations. The statistical significance among controls and treatments was established 
by one-way analysis of variance with the p value set at ≤0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This work was funded through the NIH (Grants R21AI076309, RC4AI092624, and R56AI090803) and the U.S. 







L donovani Leishmania donovani





1. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M. Visceral 
leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007; 
5:873–882. [PubMed: 17938629] 
2. Croft SL, Seifert K, Yardley V. Current scenario of drug development for leishmaniasis. Indian J 
Med Res. 2006; 123:399–410. [PubMed: 16778319] 
Gupta et al. Page 10













3. Henderson A, Jolliffe D. Cardiac effects of sodium stibogluconate. British journal of clinical 
pharmacology. 1985; 19:73–77. [PubMed: 2983749] 
4. Sabra R, Branch RA. Amphotericin B nephrotoxicity. Drug Saf. 1990; 5:94–108. [PubMed: 
2182052] 
5. Dorlo TP, van Thiel PP, Huitema AD, Keizer RJ, de Vries HJ, Beijnen JH, de Vries PJ. 
Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents 
Chemother. 2008; 52:2855–2860. [PubMed: 18519729] 
6. Verweij J, Planting A, van der Burg M, Stoter G. A dose-finding study of miltefosine 
(hexadecylphosphocholine) in patients with metastatic solid tumours. J Cancer Res Clin Oncol. 
1992; 118:606–608. [PubMed: 1325463] 
7. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW. Failure 
of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian 
epidemic. Clin Infect Dis. 2000; 31:1104–1107. [PubMed: 11049798] 
8. Purkait B, Kumar A, Nandi N, Sardar AH, Das S, Kumar S, Pandey K, Ravidas V, Kumar M, De T, 
Singh D, Das P. Mechanism of amphotericin B resistance in clinical isolates of Leishmania 
donovani. Antimicrob Agents Chemother. 2012; 56:1031–1041. [PubMed: 22123699] 
9. Perez-Victoria FJ, Castanys S, Gamarro F. Leishmania donovani resistance to miltefosine involves a 
defective inward translocation of the drug. Antimicrob Agents Chemother. 2003; 47:2397–2403. 
[PubMed: 12878496] 
10. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, Voss A, Berman J. 
Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med. 1999; 
341:1795–1800. [PubMed: 10588964] 
11. Nwaka S, Hudson A. Innovative lead discovery strategies for tropical diseases. Nat Rev Drug 
Discovery. 2006; 5:941–955. [PubMed: 17080030] 
12. Peters W. The treatment of kala-azar–new approaches to an old problem. Indian J Med Res. 1981; 
73(Suppl):1–18.
13. Sundar S, Olliaro PL. Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed 
clinical risk management. Ther Clin Risk Manage. 2007; 3:733–740.
14. Bhattacharjee S, Gupta G, Bhattacharya P, Mukherjee A, Mujumdar SB, Pal A, Majumdar S. 
Quassin alters the immunological patterns of murine macrophages through generation of nitric 
oxide to exert antileishmanial activity. J Antimicrob Chemother. 2009; 63:317–324. [PubMed: 
19036753] 
15. Polonio T, Efferth T. Leishmaniasis: drug resistance and natural products (review). Int J Mol Med. 
2008; 22:277–286. [PubMed: 18698485] 
16. Chouhan G, Islamuddin M, Sahal D, Afrin F. Exploring the role of medicinal plant-based 
immunomodulators for effective therapy of leishmaniasis. Front Immunol. 2014; 5:193. [PubMed: 
24829566] 
17. Chan-Bacab MJ, Balanza E, Deharo E, Munoz V, Garcia RD, Pena-Rodriguez LM. Variation of 
leishmanicidal activity in four populations of Urechites andrieuxii. J Ethnopharmacol. 2003; 
86:243–247. [PubMed: 12738094] 
18. Lezama-Davila CM, Isaac-Marquez AP, Zamora-Crescencio P, Uc-Encalada Mdel R, Justiniano-
Apolinar SY, del Angel-Robles L, Satoskar A, Hernandez-Rivero L. Leishmanicidal activity of 
Pentalinon andrieuxii. Fitoterapia. 2007; 78:255–257. [PubMed: 17355903] 
19. Lezama-Davila CM, Pan L, Isaac-Marquez AP, Terrazas C, Oghumu S, Isaac-Marquez R, Pech-
Dzib MY, Barbi J, Calomeni E, Parinandi N, Kinghorn AD, Satoskar AR. Pentalinon andrieuxii 
root extract is effective in the topical treatment of cutaneous leishmaniasis caused by Leishmania 
mexicana. Phytother Res. 2014; 28:909–916. [PubMed: 24347110] 
20. Lezama-Dávila CM, Isaac-Márquez AP, Zamora-Crescencio P, Uc-Encalada MeR, Justiniano-
Apolinar SY, del Angel-Robles L, Satoskar A, Hernández-Rivero L. Leishmanicidal activity of 
Pentalinon andrieuxii. Fitoterapia. 2007; 78:255–257. [PubMed: 17355903] 
21. Pan L, Lezama-Davila CM, Isaac-Marquez AP, Calomeni EP, Fuchs JR, Satoskar AR, Kinghorn 
AD. Sterols with antileishmanial activity isolated from the roots of Pentalinon andrieuxii. 
Phytochemistry. 2012; 82:128–135. [PubMed: 22840389] 
Gupta et al. Page 11













22. Seldes AM, Anding CR, Gros EG. A new approach to the synthesis of 3β,23-diacetoxy-24-nor-5-
cholene from 3β,21-diacetoxy-5-pregnen-20-one. Steroids. 1980; 36:575–580. [PubMed: 
7456101] 
23. El Kihel L, Charles G. Preparative method for the quantitative separation of methylenic sterols 
from unsaturated sterol mixtures by chemoselective hydroxymercuration-deoxymercuration. 
Synthesis. 2006:2753–2759.
24. Ryer AI, Gebert WH. 3β-Acetoxy-20-hydroxy-5-cholenic acid lactone, a by-product of the 
oxidation of cholesterol. J Am Chem Soc. 1952; 74:4336–4339.
25. Honda T, Katoh M, Yamane S-i. I. Stereoselective synthesis of petrosterol and a formal synthesis 
of aragusterols. J Chem Soc., Perkin Trans. 1996; 1:2291–2296.
26. Sheikh YM, Djerassi C. Mass spectrometry in structural and stereochemical problems CCXXX 
Preparation of 5α,20α- and 5α,17α,20α-cholestane-3β,6α-diol Electron impact induced 
fragmentation of steroidal Δ17(20), Δ20(21), and Δ20(22) olefins. J Org Chem. 1973; 38:3545–3554.
27. Nicolaou KC, Daines RA, Chakraborty TK, Ogawa Y. Total synthesis of amphotericin B. J Am 
Chem Soc. 1987; 109:2821–2822.
28. Worthen DR, Jay M, Bummer PM. Methods for the recovery and purification of polyene 
antifungals. Drug Dev Ind Pharm. 2001; 27:277–286. [PubMed: 11411895] 
29. Beach DH, Holz GG Jr, Anekwe GE. Lipids of Leishmania promastigotes. J Parasitol. 1979; 
65:203–216.
30. Vermeersch M, da Luz RI, Tote K, Timmermans JP, Cos P, Maes L. In vitro susceptibilities of 
Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: 
practical relevance of stage-specific differences. Antimicrob Agents Chemother. 2009; 53:3855–
3859. [PubMed: 19546361] 
31. Turley SD, Dietschy JM. Sterol absorption by the small intestine. Curr Opin Lipidol. 2003; 
14:233–240. [PubMed: 12840653] 
32. Shi Y, Porter W, Merdan T, Li LC. Recent advances in intravenous delivery of poorly water-soluble 
compounds. Expert Opin Drug Delivery. 2009; 6:1261–1282.
33. Cowan MM. Plant products as antimicrobial agents. Clin Microbiol Rev. 1999; 12:564–582. 
[PubMed: 10515903] 
34. Croft SL, Davidson RN, Thornton EA. Liposomal amphotericin B in the treatment of visceral 
leishmaniasis. J Antimicrob Chemother. 1991; 28(Suppl. B):111–118.
35. Hartmann MA. Plant sterols and the membrane environment. Trends Plant Sci. 1998; 3:170–175.
36. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood 
and enhanced uptake by tumors. Proc Natl Acad Sci U S A. 1988; 85:6949–6953. [PubMed: 
3413128] 
37. Sou K, Goins B, Oyajobi BO, Travi BL, Phillips WT. Bone marrow-targeted liposomal carriers. 
Expert Opin Drug Delivery. 2011; 8:317–328.
38. Litzinger DC, Buiting AM, van Rooijen N, Huang L. Effect of liposome size on the circulation 
time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. 
Biochim Biophys Acta, Biomembr. 1994; 1190:99–107.
39. Carter KC, Sundar S, Spickett C, Pereira OC, Mullen AB. The in vivo susceptibility of Leishmania 
donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione 
biosynthesis. Antimicrob Agents Chemother. 2003; 47:1529–1535. [PubMed: 12709318] 
40. D’Arcy PF, Harron DWG. Tropical diseases – leishmaniasi. Pharm Int. 1983; 4:238–243.
41. Tropia de Abreu R, Carvalho M, Carneiro CM, Giunchetti RC, Teixeira-Carvalho A, Martins-Filho 
OA, Coura-Vital W, Correa-Oliveira R, Reis AB. Influence of clinical status and parasite load on 
erythropoiesis and leucopoiesis in dogs naturally infected with leishmania (Leishmania) chagasi. 
PLoS One. 2011; 6:e18873. [PubMed: 21572995] 
42. Sharma M, Sehgal R, Kaur S. Evaluation of nephroprotective and immunomodulatory activities of 
antioxidants in combination with cisplatin against murine visceral leishmaniasis. PLoS Neglected 
Trop Dis. 2012; 6:e1629.
43. Wege AK, Florian C, Ernst W, Zimara N, Schleicher U, Hanses F, Schmid M, Ritter U. Leishmania 
major infection in humanized mice induces systemic infection and provokes a nonprotective 
human immune response. PLoS Neglected Trop Dis. 2012; 6:e1741.
Gupta et al. Page 12













44. Gupta G, Bhattacharjee S, Bhattacharyya S, Bhattacharya P, Adhikari A, Mukherjee A, 
Bhattacharyya Majumdar S, Majumdar S. CXC chemokine-mediated protection against visceral 
leishmaniasis: involvement of the proinflammatory response. J Infect Dis. 2009; 200:1300–1310. 
[PubMed: 19743920] 
45. Murray HW, Delph-Etienne S. Roles of endogenous gamma interferon and macrophage 
microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. 
Infect Immun. 2000; 68:288–293. [PubMed: 10603400] 
46. Jarvis JN, Lockwood DN. Clinical aspects of visceral leishmaniasis in HIV infection. Curr Opin 
Infect Dis. 2013; 26:1–9. [PubMed: 23221770] 
47. Satoskar A, Bluethmann H, Alexander J. Disruption of the murine interleukin-4 gene inhibits 
disease progression during Leishmania mexicana infection but does not increase control of 
Leishmania donovani infection. Infect Immun. 1995; 63:4894–4899. [PubMed: 7591152] 
48. Alexander J, Carter KC, Al-Fasi N, Satoskar A, Brombacher F. Endogenous IL-4 is necessary for 
effective drug therapy against visceral leishmaniasis. Eur J Immunol. 2000; 30:2935–2943. 
[PubMed: 11069076] 
49. Stager S, Alexander J, Carter KC, Brombacher F, Kaye PM. Both interleukin-4 (IL-4) and IL-4 
receptor alpha signaling contribute to the development of hepatic granulomas with optimal 
antileishmanial activity. Infect Immun. 2003; 71:4804–4807. [PubMed: 12874364] 
50. Wang ZE, Reiner SL, Zheng S, Dalton DK, Locksley RM. CD4+ effector cells default to the Th2 
pathway in interferon gamma-deficient mice infected with Leishmania major. J Exp Med. 1994; 
179:1367–1371. [PubMed: 7908325] 
51. Yoshida A, Koide Y, Uchijima M, Yoshida TO. IFN-gamma induces IL-12 mRNA expression by a 
murine macrophage cell line, J774. Biochem Biophys Res Commun. 1994; 198:857–861. 
[PubMed: 7906942] 
52. Paul J, Karmakar S, De T. TLR-mediated distinct IFN-γ/IL-10 pattern induces protective immunity 
against murine visceral leishmaniasis. Eur J Immunol. 2012; 42:2087–2099. [PubMed: 22622993] 
53. Stäger S, Alexander J, Carter KC, Brombacher F, Kaye PM. Both interleukin-4 (IL-4) and IL-4 
receptor alpha signaling contribute to the development of hepatic granulomas with optimal 
antileishmanial activity. Infect Immun. 2003; 71:4804–4807. [PubMed: 12874364] 
54. Parinandi NL, Weis BK, Natarajan V, Schmid HH. Peroxidative modification of phospholipids in 
myocardial membranes. Arch Biochem Biophys. 1990; 280:45–52. [PubMed: 2353824] 
55. Parinandi NL, Weis BK, Schmid HH. Assay of cardiolipin peroxidation by high-performance 
liquid chromatography. Chem Phys Lipids. 1988; 49:215–220. [PubMed: 3240565] 
56. Hinzey AH, Kline MA, Kotha SR, Sliman SM, Butler ES, Shelton AB, Gurney TR, Parinandi NL. 
Choice of cyclodextrin for cellular cholesterol depletion for vascular endothelial cell lipid raft 
studies: cell membrane alterations, cytoskeletal reorganization and cytotoxicity. Indian J Biochem 
Biophys. 2012; 49:329–341. [PubMed: 23259319] 
57. Delgado G, Puentes F, Moreno A, Patarroyo ME. Flow cytometry, a useful tool for detecting the 
lethal effect of pentamidine on Leishmania viannia complex promastigote forms. Pharmacol Res. 
2001; 44:281–286. [PubMed: 11592861] 
58. Lezama-Dávila CM, Isaac-Márquez AP, Barbi J, Oghumu S, Satoskar AR. 17Beta-estradiol 
increases Leishmania mexicana killing in macrophages from DBA/2 mice by enhancing 
production of nitric oxide but not pro-inflammatory cytokines. Am J Trop Med Hyg. 2007; 
76:1125–1127. [PubMed: 17556622] 
59. Al-Nasiry S, Geusens N, Hanssens M, Luyten C, Pijnenborg R. The use of Alamar Blue assay for 
quantitative analysis of viability, migration and invasion of choriocarcinoma cells. Hum Reprod. 
2007; 22:1304–1309. [PubMed: 17307808] 
60. Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine: oral treatment of visceral 
leishmaniasis in mice. Antimicrob Agents Chemother. 1992; 36:1630–1634. [PubMed: 1329624] 
61. Murray HW. Mononuclear cell recruitment, granuloma assembly, and response to treatment in 
experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent 
regulation. Infect Immun. 2000; 68:6294–6299. [PubMed: 11035738] 
62. Rosas LE, Satoskar AA, Roth KM, Keiser TL, Barbi J, Hunter C, de Sauvage FJ, Satoskar AR. 
Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance 
Gupta et al. Page 13













to leishmania donovani infection but develop severe liver immunopathology. Am J Pathol. 2006; 
168:158–169. [PubMed: 16400019] 
63. Ahmed SA, Gogal RM Jr, Walsh JE. A new rapid and simple non-radioactive assay to monitor and 
determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J 
Immunol Methods. 1994; 170:211–224. [PubMed: 8157999] 
64. Barbi J, Oghumu S, Lezama-Davila CM, Satoskar AR. IFN-gamma and STAT1 are required for 
efficient induction of CXC chemokine receptor 3 (CXCR3) on CD4+ but not CD8+ T cells. Blood. 
2007; 110:2215–2216. [PubMed: 17785588] 
65. Spandidos A, Wang X, Wang H, Seed B. PrimerBank: a resource of human and mouse PCR primer 
pairs for gene expression detection and quantification. Nucleic Acids Res. 2010; 38:D792–799. 
[PubMed: 19906719] 
66. Spandidos A, Wang X, Wang H, Dragnev S, Thurber T, Seed B. A comprehensive collection of 
experimentally validated primers for Polymerase Chain Reaction quantitation of murine transcript 
abundance. BMC Genomics. 2008; 9:633. [PubMed: 19108745] 
67. Wang X, Seed B. A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res. 
2003; 31:e154. [PubMed: 14654707] 
Gupta et al. Page 14














Synthesis of Pentalinonsterol (1) from Pregnenolone (2)
Gupta et al. Page 15














Fatty acid disruption in Leishmania donovani promastigotes by PEN. Shown are fatty acid 
compositions of L. donovani promastigotes treated with or without PEN (5 and 10 μg/mL) 
for 12 h. Fatty acids in total membrane lipids were derivatized into methyl esters by alkaline 
methanolysis and analyzed by gas chromatography–mass spectrometry. C16:0 = palmitic 
acid; C18:0 = stearic acid; C18:1 = oleic acid; C18:2 = linoleic acid; C20:4 = arachidonic 
acid; C22:6 = docosahexenoic acid. Data are presented as mean ± standard deviation (SD) of 
three replicates. Statistical significance with respect to 0 μg/mL PEN is presented as * p < 
0.05.
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In vitro antileishmanial activity of PEN. (A) Percentage killing of dsRed-expressing L. 
donovani promastigotes following incubation with different doses of PEN at 48 h post 
incubation as calculated by flow cytometry. (B) Percentage of viable macrophages following 
treatment with different doses of PEN at 48 h post incubation as calculated by the addition 
of Alamar blue. (C) Number of intracellular L. donovani amastigotes following treatment 
with indicated doses of PEN at 48 h post incubation as calculated by microscopic counting 
of the infected macrophages. Data are shown as mean ± standard error of the mean (SEM) of 
three replicates for each treatment and are representative of three individual experiments. 
Statistical significance with respect to DMSO-treated cells is presented as ** p < 0.01 and 
*** p < 0.001.
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Liposomal PEN treatment renders protection against L. donovani-infected mice. (A) Liver, 
(B) spleen, and (C) bone marrow parasite loads in L. donovani-infected BALB/c mice 
treated with either PBS, empty liposomes, PEN-loaded liposomes (50 μg or 2.5 mg/kg of 
body weight), or sodium stibogluconate (SSG) (70 mg/kg of body weight). Parasite burdens 
in spleen and liver are expressed as mean Leishman Donovan units (LDU); the parasite 
burden in bone marrow is expressed as number of amastigotes per 200 macrophages. The 
data are presented as mean ± SEM from four or five individual mice per group at each time 
point in three independent experiments with similar results. Significance is presented as *** 
p < 0.001.
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Effect of liposomal PEN treatment on serum aminotransferase enzymes in L. donovani-
infected mice. Shown are quantifications of the liver enzymes (A) alanine aminotransferase 
(ALT) and (B) aspartate aminotransferase (AST) in the serum of mice infected with L. 
donovani. Mice were treated 2 weeks post infection with either empty or PEN-loaded 
liposomes (50 μg or 2.5 mg/kg of body weight). Blood was collected 2 weeks post injection 
for analysis of serum enzymes. Data are shown as mean ± SEM of triplicates from four or 
five individual mice per group and are representative of three individual experiments. 
Significance with respect to empty liposomes is presented as * p < 0.05.
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Effect of liposomal PEN treatment on T cell proliferation in L. donovani-infected mice. 
Shown is the proliferation of splenic T cells of BALB/c mice infected with L. donovani in 
response to L. donovani antigen. Mice were treated 2 weeks post infection with PBS, empty 
liposomes, or PEN-loaded liposomes (50 μg or 2.5 mg/kg of body weight). Spleens were 
removed 2 weeks post injection and pulsed with L. donovani antigen (20 μg/mL), and T cell 
proliferation was measured after 72 h. Data are shown as mean ± SEM of triplicates from 
four or five individual mice per group and are representative of three individual experiments. 
Significance with respect to PBS treatment is presented as *** p < 0.001.
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Effect of liposomal PEN treatment on cytokine release in L. donovani-infected mice. (A–D) 
TH1 and TH2 cytokine production by splenocytes from L. donovani-infected mice treated 
with PBS, empty liposomes, or PEN-loaded liposomes and stimulated with 20 μg/mL L. 
donovani antigen, as measured by ELISA: (A) IFN-γ; (B) IL-10; (C) IL-4; (D) IL-13. Data 
are shown as mean ± SEM of triplicates from four or five individual mice per group and are 
representative of three individual experiments. Significance with respect to empty liposomes 
is presented as ** p < 0.01.
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Effect of liposomal PEN treatment on cytokine transcription in L. donovani-infected mice. 
(A–F) TH1 cytokine and TH2 mRNA expression by spleen tissue from L. donovani-infected 
mice treated with empty or PEN-loaded liposomes, as measured by real-time PCR: (A) IFN-
γ mRNA; (B) IL-12p35 mRNA; (C) TNF-α mRNA; (D) IL-10 mRNA; (E) IL-4 mRNA; (F) 
IL-13 mRNA. (G, H) Ratios of (G) IFN-γ to IL-10 mRNA and (H) IFN-γ to IL-4 mRNA. 
Data are shown as mean ± SEM of triplicates from four or five individual mice per group 
and are representative of three individual experiments. Significance with respect to empty 
liposomes is presented as ** p < 0.01.
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Effect of liposomal PEN treatment on hepatic granuloma formation in L. donovani-infected 
mice. (A) Liver sections from L. donovani-infected mice treated with PBS, empty 
liposomes, or PEN-loaded liposomes were scored for the extent of granuloma formation. 
Results from one representative experiment of three with similar findings are shown. Data 
are expressed as mean number of granulomas per 10 high-power fields (magnification 400×) 
± SEM. Significance compared with empty-liposome-treated groups is expressed as * p < 
0.05 and ** p < 0.01. (B) Histopathology of infected livers from L. donovani-infected mice 
treated with PBS, empty liposomes, or PEN-loaded liposomes. Both PBS- and empty-
liposome-treated mice had poorly formed granulomas that were highly parasitized (arrows). 
In contrast, mice treated with PEN-loaded liposomes had well-formed granuloma that were 
mostly devoid of parasites (400×).
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